K
Katalin Karikó
Researcher at University of Pennsylvania
Publications - 132
Citations - 18207
Katalin Karikó is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Messenger RNA & RNA. The author has an hindex of 54, co-authored 122 publications receiving 13186 citations. Previous affiliations of Katalin Karikó include Pennsylvania State University & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
TL;DR: It is concluded that nucleoside modifications suppress the potential of RNA to activate DCs, and the innate immune system may detect RNA lacking nucleosides modification as a means of selectively responding to bacteria or necrotic tissue.
Journal ArticleDOI
mRNA-based therapeutics — developing a new class of drugs
TL;DR: This Review provides a comprehensive overview of the current state of mRNA-based drug technologies and their applications, and discusses the key challenges and opportunities in developing these into a new class of drugs.
Journal ArticleDOI
COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.
Ugur Sahin,Alexander Muik,Evelyna Derhovanessian,Isabel Vogler,Lena M. Kranz,Mathias Vormehr,Alina Baum,Kristen E. Pascal,Jasmin Quandt,Daniel Maurus,Sebastian Brachtendorf,Verena Lörks,Julian Sikorski,Rolf Hilker,Dirk Becker,Ann Kathrin Eller,Jan Grützner,Carsten Boesler,Corinna Rosenbaum,Marie Cristine Kühnle,Ulrich Luxemburger,Alexandra Kemmer-Brück,David J. Langer,Martin Bexon,Stefanie Bolte,Katalin Karikó,Tania Palanche,Boris Fischer,Armin Schultz,Pei Yong Shi,Camila R. Fontes-Garfias,John L. Perez,Kena A. Swanson,Jakob Loschko,Ingrid L. Scully,Mark Cutler,Warren Kalina,Christos A. Kyratsous,David A. Cooper,Philip R. Dormitzer,Kathrin U. Jansen,Özlem Türeci +41 more
TL;DR: The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
Journal ArticleDOI
Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.
Katalin Karikó,Hiromi Muramatsu,Frank A. Welsh,Janos Ludwig,Hiroki Kato,Shizuo Akira,Drew Weissman +6 more
TL;DR: It is found that mRNAs containing pseudouridines have a higher translational capacity than unmodified m RNAs when tested in mammalian cells and lysates or administered intravenously into mice at 0.015-0.15 mg/kg doses.
Journal ArticleDOI
mRNA Is an Endogenous Ligand for Toll-like Receptor 3
TL;DR: Evidence is presented that heterologous RNA released from or associated with necrotic cells or generated by in vitro transcription also stimulates TLR3 and induces immune activation and this finding has potential physiologic relevance because RNA escaping from damaged tissue or contained within endocytosed cells could serve as an endogenous ligand forTLR3 that induces or otherwise modulates immune responses.